Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI.

Br J Pharmacol. 2012 May;166(1):4-17. doi: 10.1111/j.1476-5381.2012.01871.x. Review.

2.

Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.

Valiante S, Prisco M, Sciarrillo R, De Falco M, Capaldo A, Gay F, Andreuccetti P, Laforgia V, Varano L.

J Endocrinol. 2008 Feb;196(2):291-303. doi: 10.1677/JOE-07-0127.

3.

Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.

Mazzocchi G, Malendowicz LK, Rebuffat P, Gottardo L, Nussdorfer GG.

J Clin Endocrinol Metab. 2002 Jun;87(6):2575-80.

PMID:
12050216
4.
5.
6.
7.
9.
10.

Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.

Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K.

Neuroscience. 2012 Jan 27;202:158-68. doi: 10.1016/j.neuroscience.2011.10.055. Epub 2011 Nov 7.

PMID:
22108610
11.
12.

Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland.

Conconi MT, Spinazzi R, Nussdorfer GG.

Int Rev Cytol. 2006;249:1-51. Review.

PMID:
16697281
13.

Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.

Simonneaux V, Kienlen-Campard P, Loeffler JP, Basille M, Gonzalez BJ, Vaudry H, Robberecht P, Pévet P.

Neuroscience. 1998 Aug;85(3):887-96.

PMID:
9639281
14.

Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung.

Busto R, Carrero I, Guijarro LG, Solano RM, Zapatero J, Noguerales F, Prieto JC.

Am J Physiol. 1999 Jul;277(1 Pt 1):L42-8.

15.

VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.

Akesson L, Ahrén B, Edgren G, Degerman E.

Endocrinology. 2005 Feb;146(2):744-50. Epub 2004 Oct 28.

PMID:
15514088
16.

Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H.

Pharmacol Rev. 2000 Jun;52(2):269-324. Review.

17.

Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.

Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC.

Endocrinology. 1996 Jul;137(7):2815-22.

PMID:
8770902
20.

Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat.

Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I.

Eur J Pharmacol. 2011 Nov 16;670(1):186-94. doi: 10.1016/j.ejphar.2011.08.016. Epub 2011 Sep 2.

PMID:
21914446

Supplemental Content

Support Center